radioimmunotherapy; radiotherapy; Compared RT + RIT
Abstract :
[en] Timing effects of radioimmunotherapy (HIT) combined with external
beam radiotherapy (RT) were assessed In human colon carcinoma xe
nografts. Initially, dose effects offractlonated RT and RIT were evaluated
separately. Then, 30 Gy RT (10 fractions over 12 days) were combined
with three weekly Lv. injections of 200 g@Ci of 131I-labeled anti-carcino
embryonic antigen monoclonal antibodies in four different treatment
schedules. RIT was given either prior to, concurrently, Immediately after,
or 2 weeks after RT administration. The longest regrowth delay (RD) of
105 days was observed in mice treated by concurrent administration of
RT and lilT, whereas the RDs of RT and RIT alone were 34 and 20 days,
respectively. The three sequential combination treatments produced sig
nificantly shorter RDs ranging from 62 to 70 days. The tumor response
represented by the minimal volume (MV) also showed that concurrent
administration of RT and RIT gave the best result, with a mean MV of
4.5% as compared to MVs from 26 to 53% for the three sequential
treatments. The results were confirmed In a second experiment, In which
a RT of 40 Gy was combined with an identical lilT as above (three
injections of 200 g&Ci of ‘31I-labeled monoclonal antibodies). At compa
rable toxicity levels, the maximum tolerated RT or BIT alone gave shorter
RDs and less tumor shrinkage compared to slinultaneous RT+RIT. These
results may be useful for designing clinical protocols ofcombined RIT and
RT.
Disciplines :
Oncology Hematology
Author, co-author :
Lin-Quan, Sun; University Hospital of Geneva > Nuclear Medicine > Geneva 14, Switzerland.
Vogel, Charles-André; University Hospital of Geneva > Nuclear Medicine > Geneva 14, Switzerland.
Mirimanoff, René-Olivier; University Hospital of Geneva and University Hospital of Lausanne > Radiation Oncology and Division of Nuclear Medicine > Switzerland
Coucke, Philippe ; University Hospital of Lausanne > Radiation Oncology > 1011 Lausanne
Slosman, D-O
Buchegger, F
Language :
English
Title :
Timing effect of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice.
Publication date :
1997
Journal title :
Cancer Research
ISSN :
0008-5472
eISSN :
1538-7445
Publisher :
American Association for Cancer Research, Inc. (AACR), Baltimore, United States - Maryland
Press, O.W., Eary, J.F., Appelbaum, F.R., Martin, P.J., Nelp, W.B., Glenn, S., Fisher, D.R., Bernstein, I.D., Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas (1995) Lancet, 346, pp. 336-340
Mach, J.-P., Pèlegrin, A., Buchegger, F., Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors (1991) Curr. Opin. Immunol., 3, pp. 685-693
Goldenberg, D.M., Schlom, J., The coming of age of cancer radioimmunoconjugates (1993) Imrnunol. Today, 14, pp. 5-7
Buchsbaum, D.J., Experimental approaches to increase radiolabeled antibody localization in tumors (1995) Cancer Res., 55, pp. 5729-5732
Knox, S.J., Overview of studies on experimental radioimmunotherapy (1995) Cancer Res., 55, pp. 5832s-5836s
Goldenberg, D.M., Monoclonal antibodies in cancer detection and therapy (1993) Am. J. Med., 94, pp. 297-312
Mello, A.M., Pauwels, E.K.J., Cleton, F.J., Radioimmunotherapy: No news from the newcomer (1994) J. Cancer Res. Clin. Oncol., 720, pp. 121-130
Riethmüller, G., Schneider-Gädicke, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Witte, J., Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma (1994) Lancet, 343, pp. 1177-1183
Vitetta, E.S., Uhr, J.W., Monoclonal antibodies as agonists: An expanded role for their use in cancer therapy (1994) Cancer Res., 54, pp. 5301-5309
Suit, H.D., Local control and patient survival (1992) Int. J. Radiat. Oncol. Biol. Phys., 23, pp. 653-660
Shrivastava, S., Schlom, J., Raubitschek, A., Molinolo, A., Hand, P.H., Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts (1989) Int. J. Radiat. Oncol. Biol. Phys., 16, pp. 721-729
Msirikale, J.S., Kein, J.L., Schroeder, J., Order, S.E., Radiation enhancement of radiolabelled antibody deposition in tumors (1987) Int. J. Radiat. Oncol. Biol. Phys., 13, pp. 1839-1844
Kalofonos, H., Rowlinson, G., Epenetos, A.A., Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation (1990) Cancer Res., 50, pp. 159-163
Order, S.E., Stillwagon, G.B., Klein, J.L., Leichner, P.K., Siegelman, S.S., Fischman, E.K., Ettinger, D.S., Leibel, S., Iodine 131 antiferrin, a new treatment modality in hepatoma: A radiation therapy oncology group study (1985) J. Clin. Oncol., 3, pp. 1573-1582
Maraveyas, A., Myers, M., Stafford, N., Rowlinson-Busza, G., Stewart, J.S., Epenetos, A.A., Radiolabeled antibody combined with external radiotherapy for the treatment of head and neck cancer: Reconstruction of a theoretical phantom of the larynx for radiation dose calculation to local tissues (1995) Cancer Res., 55, pp. 1020-1027
Amin, A.E., Wheldon, T.E., O'Donoghue, J.A., Gaze, M.N., Barren, A., Optimum combination of targeted 131I and total body irradiation for treatment of disseminated cancer (1995) Int. J. Radial. Oncol. Biol. Phys., 32, pp. 713-721
Wang, S., Quadri, S.M., Tang, X.Z., Stephens, L.C., Lollo, C.P., Bartholomew, R.M., Vriesendorp, H.M., Liver toxicity induced by combined external-beam irradiation and radioimmunoglobulin therapy (1995) Radiat. Res., 141, pp. 294-302
Buchegger, F., Rojas, A., Bischof Delaloye, A., Vogel, C.A., Mirimanoff, R.-O., Coucke, P., Sun, L.-Q., Mach, J.-P., Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice (1995) Cancer Res., 55, pp. 83-89
Mach, J.-P., Carrel, S., Merenda, C., Sordat, B., Cerottini, J.-C., In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice (1974) Nature (Lond.), 248, pp. 704-706
Buchegger, F., Vacca, A., Carrel, S., Schreyer, M., Mach, J.-P., Radioimmuno-therapy of human colon carcinoma by 131-I-labelled monoclonal anti-CEA antibodies in a nude mouse model (1988) Int. J. Cancer, 41, pp. 127-134
Buchegger, F., Pfister, C., Fournier, K., Prevel, F., Schreyer, M., Carrel, S., Mach, J.-P., Ablation of human colon carcinoma in nude mice by 131-I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments (1989) J. Clin. Invest, 83, pp. 1449-1456
Hammarstrom, S., Shively, J.E., Paxton, R.J., Beatty, B.G., Larson, A., Ghosh, R., Bormer, O., Tsujisaki, M., Antigenic sites in carcinoembryonic antigen (1989) Cancer Res., 49, pp. 4852-4858
Vogel, C.A., Bischof Delaioye, A., Mach, J.-P., Pèlegrin, A., Hardman, N., Delaloye, B., Buchegger, F., Direct comparison of a radioiodinated intact chimeric anti-CEA Mab with its F(ab')2 fragment in nude mice bearing different colon cancer xenografts (1993) Br. J. Cancer, 68, pp. 684-690
Buchegger, F., Chalandon, Y., Pèlegrin, A., Hardman, N., Mach, J.-P., Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or F(ab')2 fragments (1991) J. Nucl. Med., 32, pp. 1414-1421
Johns, H.E., Cunningham, J.R., The physics of radiology (1978) Monograph in the Bannerstane Division of American Lectures in Radiation Therapy, pp. 564-574. , M Friedman (ed.), Springfield, IL: Charles C. Thomas Publisher
Hardman, N., Lee Gill, L., De Winter, R.F.J., Wagner, K., Hollis, M., Businger, F., Ammaturo, D., Heusser, C., Generation of a recombinant human-mouse chimaeric monoclonal antibody directed against human carcinoembryonic antigen (1989) Int. J. Cancer, 44, pp. 424-433
Schlom, J., Molinolo, A., Simpson, J.F., Siler, K., Roselli, M., Hinkle, G., Houchens, D.P., Colcher, D., Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy (1990) J. Natl. Cancer Inst., 82, pp. 763-771
Buchsbaum, D., Khazaeli, M.B., Liu, T., Bright, S., Richardson, K., Jones, M., Meredith, R., Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49 (1995) Cancer Res., 55, pp. 5881-5887
Schaake-Koning, K., Van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., Van Houtte, P., Kirkpatrick, A., Bartelink, H., Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer (1992) New Engl. J. Med., 326, pp. 524-530
Thames, H.D., Hendry, J.H., Biological and chemical modifiers of cell survival (1987) Fractionation in Radiotherapy, pp. 189-199. , H. D. Thames and J. H. Hendry (eds.) Philadelphia: Taylor & Francis, Inc
Folli, S., Pèlegrin, A., Chalandon, Y., Yo, X., Buchegger, F., Lejeune, F., Mach, J.-P., Tumor necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by selective increase of vascular permeability (1993) Int. J. Cancer, 53, pp. 829-836
Jain, R.K., Determinants of tumor blood flow: A review (1988) Cancer Res., 48, pp. 2641-2658
Langmuir, V.K., Fowler, J.F., Knox, S.J., Wessels, B.W., Sutherland, R.M., Wong, J.Y.C., Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry (1993) Med. Phys. (NY), 20, pp. 601-610
Vogel, C.-A., Galmiche, M.C., Buchegger, F., Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice (1997) Cancer Res., 57, pp. 447-453